PARP inhibitor olaparib slows progression of advanced prostate cancer

Bookmark and Share
Published: 30 Sep 2019
Views: 748
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA

Prof Maha Hussain presents data from the PROfound trial during a press conference at the 2019 ESMO congress.

This was a trial evaluating the PARP inhibitor olaparib vs new hormonal agents in patients with metastatic, pre-treated prostate cancer whose cancer cells had faulty DNA repair genes.

Watch Prof Hussain's interview with ecancer here.

Watch Dr Ignacio Duran's comment here

Read more about the study here.